ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.726,76
-0,21%
S&P 500
5.321,41
0,25%
Dow Jones
39.872,99
0,17%
Euro vs US Dollar
1,08545
-0,05%
Bitcoin
69.586,02
-2,61%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Dare Bioscience Inc (DARE)

  7. Dare Bioscience Inc (DARE) News

DARE

Dare Bioscience (DARE)

Dare Bioscience Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:DARE
DatumZeitQuelleÜberschriftSymbolFirma
14/05/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DAREDare Bioscience Inc
14/05/202414h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
14/05/202414h00GlobeNewswire Inc.Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company UpdateNASDAQ:DAREDare Bioscience Inc
13/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DAREDare Bioscience Inc
10/05/202422h12Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DAREDare Bioscience Inc
07/05/202414h00GlobeNewswire Inc.Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024NASDAQ:DAREDare Bioscience Inc
02/05/202414h00GlobeNewswire Inc.Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke NetworkNASDAQ:DAREDare Bioscience Inc
30/04/202413h30GlobeNewswire Inc.Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key CatalystsNASDAQ:DAREDare Bioscience Inc
23/04/202414h00GlobeNewswire Inc.Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1NASDAQ:DAREDare Bioscience Inc
11/04/202414h00GlobeNewswire Inc.Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal ContraceptiveNASDAQ:DAREDare Bioscience Inc
28/03/202413h00GlobeNewswire Inc.Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company UpdateNASDAQ:DAREDare Bioscience Inc
28/03/202412h42IH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:DAREDare Bioscience Inc
21/03/202413h00GlobeNewswire Inc.Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024NASDAQ:DAREDare Bioscience Inc
22/02/202414h00GlobeNewswire Inc.Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual MeetingNASDAQ:DAREDare Bioscience Inc
31/01/202414h00GlobeNewswire Inc.Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024NASDAQ:DAREDare Bioscience Inc
29/01/202422h18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DAREDare Bioscience Inc
26/01/202423h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
26/01/202422h30GlobeNewswire Inc.Daré Bioscience Announces Executive Team and Board of Directors ChangesNASDAQ:DAREDare Bioscience Inc
19/01/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
17/01/202414h00GlobeNewswire Inc.Daré Bioscience Announces Grant to Support Biotherapeutic Product DevelopmentNASDAQ:DAREDare Bioscience Inc
08/01/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
04/01/202414h00GlobeNewswire Inc.Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of DiseasesNASDAQ:DAREDare Bioscience Inc
26/12/202322h05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:DAREDare Bioscience Inc
26/12/202314h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
26/12/202314h00GlobeNewswire Inc.Daré Bioscience Secures $12 million in Royalty-backed Investment StructureNASDAQ:DAREDare Bioscience Inc
20/12/202314h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAREDare Bioscience Inc
20/12/202314h00GlobeNewswire Inc.Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical StudyNASDAQ:DAREDare Bioscience Inc
13/12/202314h00GlobeNewswire Inc.Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical StudyNASDAQ:DAREDare Bioscience Inc
07/12/202314h00GlobeNewswire Inc.Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with MenopauseNASDAQ:DAREDare Bioscience Inc
04/12/202314h00GlobeNewswire Inc.Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal ContraceptiveNASDAQ:DAREDare Bioscience Inc
 Showing the most relevant articles for your search:NASDAQ:DARE

Kürzlich von Ihnen besucht

LSE
51KA
Arkle 2060 A
LSE
0R06
First Solar
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten